Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension

Geeshath Jayasekera (Glasgow, United Kingdom), Geeshath Jayasekera, Martin Johnson, Colin Church, Andrew Peacock

Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Session: Pulmonary hypertension: the clinic I
Session type: Poster Discussion
Number: 1876
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Geeshath Jayasekera (Glasgow, United Kingdom), Geeshath Jayasekera, Martin Johnson, Colin Church, Andrew Peacock. Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension. Eur Respir J 2016; 48: Suppl. 60, 1876

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 370s
Year: 2002

Pathways in pulmonary arterial hypertension: the future is here
Source: Eur Respir Rev 2012 21: 321-327
Year: 2012



Hemodynamic effects of different vasodilators in patients with type II pulmonary hypertension (PH)
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014


Pulmonary hypertension in patients with COPD
Source: Eur Respir Mon 2012; 57: 138-147
Year: 2012


Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Eur Respir J 2006; 28: Suppl. 50, 399s
Year: 2006

Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013

Acute vasoresponsiveness to inhaled nitric oxide in sarcoidosis-associated pulmonary hypertension
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008


The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 3s
Year: 2001

Single arterial occlusion to locate resistance in patients with pulmonary hypertension
Source: Eur Respir J 2003; 21: 31-36
Year: 2003



Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2016; 48: 1386-1395
Year: 2016



Pulmonary hypertension: future therapies
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=84
Year: 2004

Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013

Pulmonary artery pressure and bronchial nitric oxide flux
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014

Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014

Acute vasodilator response in different forms of pre-capillary pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013

Inhaled iloprost in HIV-related pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004

Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015

Inhaled INS1009 demonstrates localized pulmonary vasodilation activity
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016


Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008

Pulmonary hypertension in COPD
Source: Eur Respir J 2008; 32: 1371-1385
Year: 2008